Financing: RECOGNISED has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847749
Duration: January 2020 – December 2023
Web: https://www.recognised.eu/
Web EU: https://cordis.europa.eu/project/id/847749
Consortium description
RECOGNISED brings together 21 partners from nine different countries, including academic institutions, small and medium enterprises (SMEs), the European infrastructure for translational medicine (EATRIS) and patient organisations, with complementary knowledge and expertise.
Project Description
“The eye as a window to the brain” – new European initiative, RECOGNISED, will determine the usefulness of the retina as a tool for identifying people with type 2 diabetes and cognitive impairment.
Type 2 diabetes is known to be an independent risk factor for developing cognitive impairment and dementia, with studies showing that people living with T2D have a two-fold higher risk of developing Alzheimer’s disease (AD) when compared to the general population. AD is a neurodegenerative disease that leads to the progressive loss of brain cells, which causes cognitive decline and, eventually, dementia. People with cognitive impairment are more prone to have impaired diabetes self-management, poor glycaemic control and an increased incidence of diabetes-related complications, which presents significant challenges both for individuals and healthcare systems on how best to manage diabetes care.
RECOGNISED project will study the biological mechanisms that cause structural and functional alterations in the retina in people with type 2 diabetes, to determine whether these same pathways play a role in the events observed in the brain during the development of cognitive impairment and dementia. Importantly, RECOGNISED will reveal whether evaluating the retina, easily accessible with current non-invasive technologies, could help in identifying earlier cognitive impairment in people with T2D, so that appropriate support can be given. RECOGNISED will also analyse previously-collected data and samples from registries, cohorts and biobanks. By gaining knowledge on the mechanisms of disease, RECOGNISED will help to identify new potential therapeutic interventions.
Financing: RECOGNISED has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847749Duration: January 2020 – December 2023
Web: https://www.recognised.eu/
Web EU: https://cordis.europa.eu/project/id/847749
Consortium description
RECOGNISED brings together 21 partners from nine different countries, including academic institutions, small and medium enterprises (SMEs), the European infrastructure for translational medicine (EATRIS) and patient organisations, with complementary knowledge and expertise.
Project Description
“The eye as a window to the brain” – new European initiative, RECOGNISED, will determine the usefulness of the retina as a tool for identifying people with type 2 diabetes and cognitive impairment.
Type 2 diabetes is known to be an independent risk factor for developing cognitive impairment and dementia, with studies showing that people living with T2D have a two-fold higher risk of developing Alzheimer’s disease (AD) when compared to the general population. AD is a neurodegenerative disease that leads to the progressive loss of brain cells, which causes cognitive decline and, eventually, dementia. People with cognitive impairment are more prone to have impaired diabetes self-management, poor glycaemic control and an increased incidence of diabetes-related complications, which presents significant challenges both for individuals and healthcare systems on how best to manage diabetes care.
RECOGNISED project will study the biological mechanisms that cause structural and functional alterations in the retina in people with type 2 diabetes, to determine whether these same pathways play a role in the events observed in the brain during the development of cognitive impairment and dementia. Importantly, RECOGNISED will reveal whether evaluating the retina, easily accessible with current non-invasive technologies, could help in identifying earlier cognitive impairment in people with T2D, so that appropriate support can be given. RECOGNISED will also analyse previously-collected data and samples from registries, cohorts and biobanks. By gaining knowledge on the mechanisms of disease, RECOGNISED will help to identify new potential therapeutic interventions.